"Melanoma, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
| Descriptor ID |
D008546
|
| MeSH Number(s) |
C04.557.465.625.650.510.525 C04.557.580.625.650.510.525 C04.557.665.510.525 C04.619.600 E05.598.500.496.937
|
| Concept/Terms |
Melanoma, Experimental- Melanoma, Experimental
- Melanomas, Experimental
- Experimental Melanoma
- Experimental Melanomas
Melanoma, B16- Melanoma, B16
- B16 Melanomas
- Melanomas, B16
- B16 Melanoma
|
Below are MeSH descriptors whose meaning is more general than "Melanoma, Experimental".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neuroendocrine Tumors [C04.557.465.625.650]
- Melanoma [C04.557.465.625.650.510]
- Melanoma, Experimental [C04.557.465.625.650.510.525]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neuroendocrine Tumors [C04.557.580.625.650]
- Melanoma [C04.557.580.625.650.510]
- Melanoma, Experimental [C04.557.580.625.650.510.525]
- Nevi and Melanomas [C04.557.665]
- Melanoma [C04.557.665.510]
- Melanoma, Experimental [C04.557.665.510.525]
- Neoplasms, Experimental [C04.619]
- Melanoma, Experimental [C04.619.600]
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Models, Animal [E05.598]
- Disease Models, Animal [E05.598.500]
- Neoplasms, Experimental [E05.598.500.496]
- Melanoma, Experimental [E05.598.500.496.937]
Below are MeSH descriptors whose meaning is more specific than "Melanoma, Experimental".
This graph shows the total number of publications written about "Melanoma, Experimental" by people in this website by year, and whether "Melanoma, Experimental" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 2 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 3 | 7 |
| 2015 | 5 | 2 | 7 |
| 2016 | 1 | 4 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 4 | 0 | 4 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melanoma, Experimental" by people in Profiles.
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.
-
Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019 12; 5(12):eaay1357.
-
Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019 04 10; 11(487).
-
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. Front Immunol. 2019; 10:294.
-
Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice. J Pharmacol Exp Ther. 2019 03; 368(3):503-513.
-
Non-canonical NF-?B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity. 2018 09 18; 49(3):490-503.e4.
-
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
-
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).
-
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
-
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med. 2017 Sep 13; 9(407).